Big Pharma Reshapes Pipelines With M&A, AI Partnerships

Gilead, Lilly, and J&J advance immunology and autoimmune franchises with strategic deals

Healthcare Market Overview

Healthcare stocks advanced Monday afternoon with the NYSE Health Care Index rising 0.6%. $ABBV gained 1.78% to close at $213.12, while $MRK dipped 1.28% to $118.10 and $ABT fell 2.03% to $101.88. $GILD traded at $136.34 with a 12.1% year-to-date return and 24.9% gain over the past year.

Big Pharma & Biotech

$GILD entered a definitive agreement to acquire Ouro Medicines and signed a collaboration with Galapagos NV to advance T cell engager therapies for autoimmune diseases. $LLY secured a $2.75 billion AI-powered drug discovery partnership with Insilico Medicine, gaining exclusive global rights to develop candidates using Insilico's platform across multiple therapeutic areas. $JNJ entered a $500 million R&D co-funding agreement with Royalty Pharma to advance JNJ-4804, a first-in-class co-antibody therapy for autoimmune diseases. $MRK's experimental cholesterol treatment easily outperformed a triplet of medications in recent data.

MedTech & Devices

$ABT and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR platform, allowing more than 1,600 community cancer centers and 4,700 providers to order tests including Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard directly within clinical workflows. This unified digital access could meaningfully enhance test adoption in routine oncology practice. $TMO faces potential headwinds from rising helium prices driven by Middle East tensions, according to Jefferies analyst commentary on March 16.

FDA & Regulation

$JNJ received U.S. FDA approval earlier in March 2026 for ICOTYDE (icotrokinra), the first targeted oral peptide blocking the IL-23 receptor for moderate-to-severe plaque psoriasis in adults and adolescents. The approval was supported by Phase 3 data in about 2,500 patients showing clear or almost clear skin with a safety profile close to placebo through 52 weeks. Market chatter suggests $LLY is seeking NHS drug price hikes in exchange for UK investment.

Looking Ahead

Galapagos and $GILD are hosting a conference call today at 14:00 CET / 8:00 am ET to discuss their T cell engager collaboration, with Galapagos retaining a majority of its cash for additional strategic transactions. Lexeo Therapeutics submitted its SUNRISE-FA 2 pivotal trial protocol for LX2006 to FDA in Q1 2026 following a Type B meeting, with study initiation on track for first half 2026. Consensus projects $JNJ's EPS CAGR of 8.9% from 2026 to 2030, with forward P/E compressing from 20.8x to 14.8x.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy